• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

American College of Allergy, Asthma & Immunology - 2024 Annual Scientific Meeting

October 24 - 27, 2024

  1. FASENRA (benralizumab)
  2. TEZSPIRE (tezepelumab)
  3. AIRSUPRA (albuterol/budesonide)
  4. Respiratory Unbranded

PDF

Nasal polyps and asthma outcomes in severe eosinophilic asthma patients by nasal polyp status: XALOC-2 real-world evidence program

pdf

Efficacy of Benralizumab and Mepolizumab on Asthma Outcomes in Patients with Eosinophilic Granulomatosis with Polyangiitis

PDF

Tezepelumab Effects on Inflammatory Biomarkers in Patients with Severe, Uncontrolled Asthma by Baseline Biomarker Level

pdf

Clinically Meaningful Lung Function, Asthma Control and Rhinosinusitis Symptom Improvements 6 Months After Tezepelumab Initiation

PDF

Early And Sustained Asthma Control Over 24 Weeks After Tezepelumab Initiation: Real-world ASCENT Study

HTML

Real-world Outcomes Following Biologic Initiation in US Patients with Chronic Rhinosinusitis with Nasal Polyposis

PDF

Does Stepping-Up Inhaled Corticosteroid Maintenance Dose Following a Severe Exacerbation Reduce Future Exacerbation Risk?

PDF

Effects of As-Needed Albuterol–Budesonide Versus Albuterol on Asthma Exacerbations and Lung Function Relative to Persistent Airflow Limitation

pdf

Patterns of As-Needed Use of Albuterol–Budesonide or Albuterol Around a Severe Exacerbation: MANDALA Post-Hoc Analysis

PDF

Disease Burden of Asthma Patients Utilizing Short-Acting Beta2-Agonist Only Inhalers as Rescue in the United States

PDF

Proportion of Patients with Severe Asthma and Comorbid Chronic Rhinosinusitis with Nasal Polyps: Literature Review

PDF

Implementing the Asthma Impairment and Risk Questionnaire and Asthma Checklist into an Asthma Coaching Program

Pdf

Parents/Caregivers, Physicians, C-ACT, and GINA Symptom Control Questions Overestimate Asthma Control for Children 5-11 Years

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Request a field medical follow-up

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice